QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 27.49
-- x --
-- x --
-- - --
$ 6.08 - $ 27.51
2,308,974
na
1.12B
$ 1.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-02-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silk-road-medical-q2-eps-042-misses-038-estimate-sales-5124m-beat-4960m-estimate

Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...

 stifel-downgrades-silk-road-medical-to-hold-raises-price-target-to-275

Stifel analyst Rick Wise downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and raises the price target from $23 to...

 argus-research-downgrades-silk-road-medical-to-sell

Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.

 lake-street-downgrades-silk-road-medical-to-hold-lowers-price-target-to-275

Lake Street analyst Frank Takkinen downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowers the price target f...

Core News & Articles

- SEC Filing

 boston-scientific-adds-stroke-prevention-to-vascular-portfolio-via-silk-road-medicals-13b-deal

Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...

Core News & Articles

Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Sil...

Core News & Articles

The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's...

 jp-morgan-maintains-neutral-on-silk-road-medical-raises-price-target-to-21

JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...

 piper-sandler-maintains-neutral-on-silk-road-medical-raises-price-target-to-20

Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION